| Biomarker ID | 1306 |
| PMID | 24394557 |
| Year | 2014 |
| Biomarker | VGLL3 + IGFBP3 + F3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: [Group 2: 3.99 (95% CI: 1.65–9.64)]; [Group 1: 7.67 (95% CI: 3.04–19.36)];Multivariate: HR: [Group 2: 2.96 (95% CI: 1.11–7.87))]; [Group 1: 7.12 (95% CI: 2.56–19.85)] |
| Effect on Pathways | NA |
| Experiment | PCa Specific Survival Vs No PCa Specific Survival |
| Type of Biomarker | Prognostic |
| Cohort | 189 patients from Swedish Cohort were selected for analysis. Survival information was available for 185 patients. 22 are alive, 98 died due to prostate cancer and 65 died due to other causes. 95 patients were used to create three tumor subtypes - Group 1,2,3 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Group2: [Univariate: p= 0.002; Multivariate: 0.030]; Group 1: p<0.0001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | VGLL3, IGFBP3, F3 |